Results 161 to 170 of about 208,301 (303)

KRAS Inhibitors in Pancreas Cancer: Facts and Hopes about the Immunotherapy We Have All Been Waiting for. [PDF]

Clin Cancer Res
Stanger BZ, Vonderheide RH.
europepmc   +1 more source

Blood‐Based Circulating Tumor DNA Assays for Early Colorectal Cancer Detection: A Systematic Review of Performance in Asymptomatic Screening Populations

International Journal of Cancer, EarlyView.
Early detection of colorectal cancer via population‐based screening programs can reduce incidence and mortality, but current screening approaches are limited. This systematic review evaluated the screening potential of blood‐based circulating tumor DNA assays in asymptomatic screening populations.
Caroline Ledertoug Kahn, Maria Wissing Rasmussen, Jakob Kleif, Inge Søkilde Pedersen, Christina Therkildsen   +4 more
wiley   +1 more source

Crosstalk between KRAS and miRNAs in pancreatic cancer: Opportunities for its diagnosis, prognosis and therapeutic intervention (Review). [PDF]

Int J Oncol
Aloliqi AA, Alnuqaydan AM, Alshebremi M, Rahmani AH, Khan AA.   +4 more
europepmc   +1 more source

Krš ili kras? Krš!

Geografski horizont, 2008
U radu se iznosi opravdanost termina krš i razlozi zbog kojih taj termin ima prednost pred terminom kras.
openaire   +3 more sources

Neoadjuvant Atezolizumab and Chemotherapy for Non‐Squamous Non‐Small Cell Lung Cancer: Efficacy and Safety Results of an Open‐Label, Single‐Arm, Phase II Trial

International Journal of Cancer, EarlyView.
Surgery plus chemotherapy is a well‐established treatment protocol for resectable, locally advanced non‐small cell lung cancer (NSCLC). Nonetheless, survival gains remain limited, emphasizing the need for more effective treatments. Here, the authors evaluated a novel approach using a neoadjuvant immunotherapy‐chemotherapy regimen consisting of ...
Benedikt Niedermaier, Tilmann Bochtler, Florian Eichhorn, Raffaella Griffo, Laura V. Klotz, Michael Allgäuer, Albrecht Stenzinger, Helge Bischoff, Marc A. Schneider, Petros Christopoulos, Uwe Haberkorn, Claus Peter Heussel, Inka Zoernig, Felix J. F. Herth, Michael Thomas, Alexander Rölle, Hauke Winter, Axel Benner, Dirk Jaeger, Martin E. Eichhorn   +19 more
wiley   +1 more source

Emerging KRAS G12D inhibitor in the treatment of digestive system tumors: opportunities and challenges. [PDF]

Transl Gastroenterol Hepatol
Wu X, Hayashi H, Tanizaki T, Sun Y, Iwatsuki M.   +4 more
europepmc   +1 more source

Silencing KRAS [PDF]

Science-Business eXchange, 2014
openaire   +1 more source

The Relevance of Curative‐Intent Metastasectomy in Colorectal Cancer Patients: Real‐World Insights From a Certified Comprehensive Cancer Center in Germany

International Journal of Cancer, EarlyView.
Patients with metastatic colorectal cancer who are ineligible for upfront metastasectomy may still become candidates for secondary metastasectomy with curative intent following response to primary chemotherapy. However, most studies dichotomize metastatic colorectal cancer into resectable and unresectable disease.
Julian W. Holch, Jo‐Ann Eisenburger, Antony Weber, Iris Kammermeier‐Wehlau, Yannick Wiberg, Fabian Allmendinger, Kathrin Heinrich, Lena Weiss, C. Benedikt Westphalen, Victoria Krenmayr, Klara Dorman, Danmei Zhang, Theres Fey, Karin Berger‐Thürmel, Ulrich Wirth, Florian Kühn, Michael von Bergwelt‐Baildon, Jens Werner, Volker Heinemann   +18 more
wiley   +1 more source

The landscape of responses to neoadjuvant immunotherapy in resectable Kirsten rat sarcoma viral oncogene homolog-mutant lung adenocarcinoma: Clinical heterogeneity and correlative immunologic analysis. [PDF]

Clin Transl Med
Wu S, Niu J, Chen X, Li J, Tang Q, Yang Z, Gao S.   +6 more
europepmc   +1 more source

KRAS Positive [PDF]

, 2020
openaire   +1 more source